Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $1.59B
• Dividend Yield: N/A
• Average Volume (3M): 1.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -100.34%
• EPS Growth: 52.85%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 109,819,570
• 10 Day Avg. Volume: 2,064,290
• 30 Day Avg. Volume: 1,771,501
• PEG Ratio: <0.01
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 2.95
• P/FCF Ratio: -1.53
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: -1.53K
• Enterprise Value/Gross Profit: -49.13
• Enterprise Value/Ebitda: -6.60
• 1Y Price Target: $20.33
• Price Target Upside: 36.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $15.00 ▲(1.01% Upside)

The score is held back primarily by weak financial performance (negative TTM revenue, large losses, and heavy cash burn) despite low leverage. Technicals are supportive with an uptrend, but overbought momentum signals add near-term risk. Earnings call factors are moderately positive due to strong cash and pipeline progress, partially offset by a key trial timeline delay. Valuation is pressured by negative earnings and no dividend support.

Positive Factors

Low Leverage / Balance Sheet Flexibility

Extremely low debt provides durable financial flexibility to fund clinical programs and absorb trial setbacks without near-term insolvency risk. This reduces bankruptcy risk and preserves strategic optionality for partnerships or selective financing over the next 2–6 months.

Strong Cash Position and Recent Financing

A $344M cash balance, bolstered by a $191M offering, materially extends runway into 2028 per management, lowering near-term refinancing pressure. This supports multiple Phase III/Phase I activities and lowers the odds of disruptive dilutive funding needs in the medium term.

Regulatory Recognition for Lead Asset

Breakthrough designation signals expedited review and regulatory priority for avexitide, improving the odds of faster approval and market access if trials succeed. That structural regulatory support enhances the commercial potential and de-risks part of the clinical development path.

Negative Factors

High Ongoing Cash Burn

Sustained negative operating and free cash flow of ~-$154M TTM erodes cash reserves and increases dependency on external financing if burn continues. Over several quarters this pressures strategic flexibility and may force dilution or spending cuts that could delay programs.

Revenue Collapse and Large Losses

A swing from prior profitability to negative TTM revenue and large losses indicates fragile earnings quality and lack of durable product revenues. This structural weakness undermines self-funding, raises execution risk, and makes future operating plans contingent on financing or successful approvals.

Delay in Key Phase III Trial

Slower enrollment and a pushed topline to Q3 2026 delays potential approval and revenue realization for a core program. The structural impact includes prolonged development costs, longer uncertainty for commercialization timing, and greater exposure to competitive or regulatory changes.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Amylyx Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, particularly AMX0035, which has received regulatory approval for use in ALS patients. The company may also explore partnerships with larger pharmaceutical firms for co-development or licensing agreements to expand its product offerings and market reach. Additionally, revenue can be supplemented through grants and funding from governmental and non-governmental organizations aimed at fostering innovation in the biotech sector. As Amylyx progresses through clinical trials and achieves regulatory milestones, it may also benefit from milestone payments from partners, further contributing to its earnings.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Balance sheet strength (very low leverage) is a key positive, but it is outweighed by sharply deteriorated operating results: TTM revenue turned negative, losses remain large, and cash flow is deeply negative with ongoing free-cash-flow burn.

Income Statement

Performance has deteriorated sharply. In TTM (Trailing-Twelve-Months), revenue turned negative (-$0.7M) versus $87.4M in 2024 and $380.8M in 2023, while losses remain very large (TTM net loss -$149.3M; 2024 net loss -$301.7M). Profitability is highly unstable year-to-year (2023 was profitable with $49.3M net income, but 2024 and TTM reverted to deep losses), suggesting weak earnings quality/visibility and a business model currently not covering its cost base.

Balance Sheet

Leverage is very low, which is a key strength: TTM debt is $5.9M against $332.0M of equity (debt-to-equity ~0.02), providing balance sheet flexibility. Assets remain sizable (TTM $362.7M), but profitability pressure is eroding returns (TTM return on equity about -0.69; 2024 about -1.83), so the main risk is continued losses reducing the equity cushion over time despite limited debt.

Cash Flow

Cash generation is weak and consistently negative. TTM operating cash flow is -$154.4M and free cash flow is -$154.5M, following -$167.6M and -$167.8M in 2024, indicating ongoing cash burn. Free cash flow has not shown sustained improvement (TTM free cash flow growth -6.7% after 2024 at -16.7%), which increases dependency on existing cash reserves and/or future financing if burn persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-665.00K	87.37M	380.79M	22.23M	0.00	650.00K
Gross Profit	-20.66M	45.22M	355.35M	19.24M	0.00	-23.94M
EBITDA	-153.71M	-290.98M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-149.28M	-301.74M	49.27M	-198.38M	-87.93M	-42.28M
Balance Sheet
Total Assets	362.74M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	343.99M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	5.93M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	30.75M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	332.00M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-154.52M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-154.45M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	49.55M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	257.35M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 14.85 is above the 20-day moving average (MA) of 13.72, above the 50-day MA of 13.53, and above the 200-day MA of 10.02, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 55.94 is Neutral, neither overbought nor oversold. The STOCH value of 41.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	81 Outperform	$2.12B	11.61	25.93%	―	21.13%	50.86%
AMLX	56 Neutral	$1.59B	-8.25	-56.52%	―	-100.34%	52.85%
DNTH	56 Neutral	$2.17B	-15.28	-28.57%	―	-42.64%	-39.78%
PHVS	56 Neutral	$1.78B	-8.64	-51.81%	―	―	-20.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCRX	51 Neutral	$1.65B	-141.01	―	―	45.38%	92.85%
BHVN	48 Neutral	$1.77B	-1.59	-522.08%	―	―	18.76%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Advances AMX0318 as New Rare-Disease Candidate

On January 8, 2026, Amylyx Pharmaceuticals selected AMX0318, a long-acting GLP-1 receptor antagonist discovered under its collaboration with peptide drug specialist Gubra A/S, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a $4 million milestone payment and positioning Gubra to earn more than $50 million in additional development and commercialization milestones plus mid-single-digit royalties on worldwide sales. The company also updated its corporate presentation in January 2026 to highlight a growing rare-disease pipeline led by avexitide, which is in a Phase 3 LUCIDITY trial for PBH with topline data expected in the third quarter of 2026 and a potential 2027 launch, while earlier clinical data have shown avexitide can sharply reduce hypoglycemic events in PBH patients, underscoring Amylyx’s strategic push to build a leading franchise in GLP-1 pathway modulation for underserved endocrine and neurodegenerative indications.

The most recent analyst rating on (AMLX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.